Meeting
2021 ASCO Annual Meeting
A randomized phase II trial of diffusion-weighted MR imaging-guided radiotherapy plus chemotherapy versus standard chemoradiotherapy in locoregional advanced nasopharyngeal carcinoma.
Authors
Feng Liu
Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
Feng Liu , Shengnan Fu , Yanzhu Chen , Ouying Yan , Lili He , Cuihong Jiang , Xiangwei Wu , Yaqian Han , Hui Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
ChiCTR1800015779
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6018)
DOI
10.1200/JCO.2021.39.15_suppl.6018
Abstract #
6018
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Recombinant human endostatin combined with intensity-modulated radiotherapy in low-risk locoregionally advanced nasopharyngeal carcinoma: A phase II, randomized, multicenter clinical trial.
First Author: Min Kang
Poster
2011 ASCO Annual Meeting
Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminary clinical results of RTOG 0615.
First Author: N. Y. Lee
Poster
2022 ASCO Annual Meeting
Neoadjuvant chemotherapy plus tislelizumab followed by concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial.
First Author: Qiu-Yan Chen